ALLO — Allogene Therapeutics, Inc.
Is ALLO overbought or oversold? Here is the current MarketMoodz read.
Allogene Therapeutics, Inc. (ALLO) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of October 3, 2026. The Healthcare name (Biotechnology) last closed at $1.50. The rating moved from Oversold to Strong Oversold on October 1, 2026.
- Public ratingStrong Oversold (as of October 3, 2026)
- Last close$1.50
- Last changeMoved from Oversold to Strong Oversold on October 1, 2026
- SectorHealthcare
- IndustryBiotechnology
See all oversold Healthcare stocks →
AI analysis
Allogene Therapeutics, Inc. remains a high-risk, binary biotech exposure whose near-term performance is driven primarily by clinical milestones, cash runway and financing options. The current market risk-off environment, payer scrutiny on drug pricing, and operational challenges inherent to allogeneic cell therapy increase the probability of dilution and execution delays. Upside would require clear, positive clinical data, a non-dilutive partnership or visible path to commercialization; absent such catalysts the equity is vulnerable to downward pressure.
Key factors
- Weak near-term market backdrop: risk-off sentiment and light volumes reduce appetite for small-cap BIO names and delay IPO/funding windows.
- Clinical & pipeline dependence: valuation and upside hinge on successful late-stage data or clear clinical progress for allogeneic cell programs; milestone binary risk remains high.
- Balance sheet & financing risk: limited publicly available EDGAR detail in the brief; historically high cash burn in cell therapy companies raises likelihood of dilution or need for partnerships.
- Commercial & payer headwinds: ongoing U.S. Medicare drug‑price negotiation and broader payer cost scrutiny increase pricing and access uncertainty for high-cost specialty therapies.
- Manufacturing & supply complexity: allogeneic cell therapies require scale-up, QC and supply-chain resilience; execution risk can materially affect timelines and costs.
- Competitive landscape: autologous CAR-T incumbents and next‑generation competitors (including combination regimens and alternative modalities) could constrain future market share.
Risks
- Negative or delayed clinical readouts that reduce program value and trigger share declines.
- Rapid cash depletion forcing dilutive equity raises or value-destructive asset sales.
- Unfavorable payer decisions or Medicare negotiation outcomes reducing addressable pricing and revenue potential.
- Manufacturing setbacks or quality control issues delaying commercialization and increasing costs.
- Increased competition from autologous CAR-T, bispecifics, gene-edited platforms and combination regimens.
- Macro/market volatility that further suppresses capital access and secondary market liquidity.
- Regulatory delays or additional safety requirements from FDA/other authorities.
Latest MarketMoodz coverage
See today's live rating, score and targets
Members see the live hourly rating for ALLO — the numeric AI score plus targets and entry zones — while this public page updates nightly.
Start the 14-day trialThis page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.